CD19 and neoplasm: All the CD19-CAR-transduced T cells demonstrated potent anti-tumor activity with a more than 60% survival rate, whereas, the CD19-CAR group with ACAT1-shRNA sets showed a more than 80% survival rate in xenograft B-cell leukemia mice model as shown in Figure 5b.